ArticleJournal of cellular and molecular medicine2024
Building a Risk Scoring Model for ARDS in Lung Adenocarcinoma Patients Using Machine Learning Algorithms.
Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD), the predominant form of non-small-cell lung cancer, is frequently complicated by acute respiratory distress syndrome (ARDS), which increases mortality risks. Investigating the prognostic implications of ARDS-related genes in LUAD is crucial for improving clinical outcomes. Data from TCGA, GEO and GTEx were used to identify 276 ARDS-related genes in LUAD via differential expression analysis. Univariate Cox regression, consensus clustering and machine learning algorithms were used to develop a prognostic risk scoring model. Functional enrichment, immune infiltration analyses, copy number variations and mutational burdens were examined, and the results were validated at the single-cell level. ARDS-related genes significantly impact the prognosis of LUAD patients. A machine learning-based risk scoring model accurately predicted survival rates. Functional enrichment and immune infiltration analyses revealed that these genes are primarily involved in cell cycle regulation and immune cell infiltration. Single-cell expression data supported these findings, and the assessments of copy number variations and mutational burdens highlighted distinct genetic characteristics. This study establishes the prognostic relevance of ARDS-associated genes in LUAD and provides potential biomarkers for personalized therapy and prognosis. Future studies will validate these findings and explore their clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.